Skip to main content

Table 3 Hazard ratio risks and log-rank tests in BR1141

From: Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

 

BRmet50

 

PMID18271932Sig33

PMID16505416Sig822

 

HR(95% CI)

HR P

HR (95% CI)

HR P

HR (95% CI)

HR P

Tumor size

      

T1

2.6(1.3-5.5)

0.009

2.4(1.1-5.0)

0.019

1.0(0.5-2.1)

0.943

T2

1.7(1.0-2.8)

0.044

2.0(1.3-3.3)

0.008

0.7(0.4-1.2)

0.209

Lymph node involvement

      

No

2.3(1.4-3.9)

0.001

2.2(1.3-3.3)

0.003

0.8(0.5-1.4)

0.511

Yes

2.0(1.0-4.1)

0.053

2.8(1.4-5.0)

0.004

0.6(0.3-1.4)

0.245

Tamoxifen treatment

      

No

2.6(1.4-5.0)

0.004

2.5(1.3-5.0)

0.007

1.1(0.5-2.0)

0.869

Yes

2.2(1.2-3.9)

0.007

2.6(1.4-5.0)

0.001

0.6(0.3-1.0)

0.041

Differentiation

      

Good

2.3(0.6-8.4)

0.196

2.5(0.8-10)

0.131

1.3(0.4-3.8)

0.682

Intermediate

2.5(1.5-4.3)

0.001

3.3(2.0-5.0)

<0.001

0.7(0.4-1.2)

0.194

Poor

1.4(0.6-3.4)

0.442

1.3(0.6-3.3)

0.554

0.5(0.2-1.1)

0.086

ER status

      

Negative

1.4(0.5-4.0)

0.495

1.7(0.6-5.0)

0.329

0.9(0.3-2.4)

0.782

Positive

2.5(1.6-4.0)

<0.001

2.5(1.7-5.0)

<0.001

0.7(0.4-1.1)

0.102

  1. Note: T1 denotes tumor size less than or equal to 2.0 cm, and T2 denotes tumor size larger than 2.0 cm.
  2. HR: Hazard ratio value.
  3. HR P: Hazard ratio P value.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us